Logo Image
|Articles|December 10, 2015

Special Section Media, Communications & Social Media

Author(s)DIA

From enhancing the clinical trial recruitment process to providing a powerful tool for communicating drug safety, mobile technology and social media are quickly becoming part of the biopharmaceutical landscape. This Special Section of the December 2015 Global Forum explores the intersection of digital technology with the patient experience, and showcases forward-thinking applications of technology into the drug development process.

To read this article, click here.

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: Nxera Licenses EP4 Agonist to AbbVie
How microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer Ingelheim’s up-to-$7 billion oncology licensing deal with Sino Biopharmaceutical and Nxera Pharma’s EP4 agonist deal with AbbVie, and CytoDyn’s Dr. Jay Lalezari on why Leronlimab isn’t just another repurposed drug.
Read more
The Promise of Microgravity for R&D and Manufacturing
The Promise of Microgravity for R&D and Manufacturing
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Read more